NEWARK, U.S.A. and NANJING, China — Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced two poster presentations featuring preclinical research data of anti-Siglec-15ⅹGM-CSF bispecific fusion molecule and novel anti-CLDN18.2 monoclonal antibody, have been presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held November 1-5, 2023, in San Diego.
BSI-706, Antibody-Drug Conjugates Targeting CLDN18.2 for the Treatment of Solid Tumors
BSI-706 is novel humanized antibody specifically targeting CLDN18.2 with favorable cell binding and internalization activity, supporting the initiation of development of ADCs including manufacturing and IND-enabling studies.
Click here for more information
BSI-510, a Novel Bispecific Molecule Combining an Anti-Siglec-15 Antibody with Cytokine GM-CSF for Enhanced Antitumor EfficacyBSI-510 is a first-in-class anti-Siglec-15ⅹGM-CSF bispecific fusion molecule combining simultaneous reversal of T cell inhibition and M2/M1 macrophage repolarization.BSI-510 demonstrates favorable biophysical and functional characteristics, supporting the initiation of development activities including manufacturing and IND-enabling studies.
Click here for more information
BIOSION ALL RIGHTS RESERVED.
NEWARK, U.S.A. and NANJING, China — Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced two poster presentations featuring preclinical research data of anti-Siglec-15ⅹGM-CSF bispecific fusion molecule and novel anti-CLDN18.2 monoclonal antibody, have been presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held November 1-5, 2023, in San Diego.
BSI-706, Antibody-Drug Conjugates Targeting CLDN18.2 for the Treatment of Solid Tumors
BSI-706 is novel humanized antibody specifically targeting CLDN18.2 with favorable cell binding and internalization activity, supporting the initiation of development of ADCs including manufacturing and IND-enabling studies.
Click here for more information
BSI-510, a Novel Bispecific Molecule Combining an Anti-Siglec-15 Antibody with Cytokine GM-CSF for Enhanced Antitumor EfficacyBSI-510 is a first-in-class anti-Siglec-15ⅹGM-CSF bispecific fusion molecule combining simultaneous reversal of T cell inhibition and M2/M1 macrophage repolarization.BSI-510 demonstrates favorable biophysical and functional characteristics, supporting the initiation of development activities including manufacturing and IND-enabling studies.
Click here for more information
BIOSION ALL RIGHTS RESERVED.